What Ранитидин Софарма Treats: Main Uses and Benefits

Ранитидин Софарма is a pharmaceutical product used in managing conditions related to excess stomach acid. The therapeutic applications are focused on addressing and relieving the associated discomfort.

The primary uses include the treatment and prevention of ulcers in the gastrointestinal tract, such as duodenal and gastric ulcers. It is also used in the management of gastroesophageal reflux disease (GERD), which involves the backward flow of stomach acid into the esophagus, commonly causing heartburn. Furthermore, this medication is indicated for treating conditions that cause the stomach to secrete an excessive amount of acid, such as Zollinger-Ellison syndrome.

The benefit of using this product is the reduction of gastric acid secretion, which helps in the healing process of ulcers and provides reliable relief from symptoms like persistent heartburn, stomach pain, and related discomfort. The treatment helps to alleviate symptoms and reduce the frequency of relapse for these acid-related issues.

---

Quick Facts

• Treats: Ulcers of the stomach and intestines.
• Treats: Gastroesophageal Reflux Disease (GERD) and associated heartburn.
• Treats: Conditions involving pathological gastric acid hypersecretion.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Ranitidine Sopharma

Eligibility for using Ranitidine Sopharma (Ranitidine Hydrochloride) is strictly defined by regulatory guidelines concerning patient demographics and pre-existing conditions.

Contraindications and Prohibited Use

Category	Population / Condition
Absolute Contraindication	Patients with a known hypersensitivity to ranitidine or any component of the formulation.
Absolute Contraindication	Patients with a history of acute porphyria, as use is avoided in this population.

---

Restricted and Conditional Use

Category	Restriction
Renal Function	Use in patients with severe renal impairment (creatinine clearance < 50 mL/min) is restricted and requires a mandatory dosage adjustment.
Hepatic Function	Caution should be observed in patients with hepatic dysfunction.
Comorbidity	The possibility of gastric malignancy must be excluded before initiating therapy, especially in middle-aged or older patients with new dyspeptic symptoms.
Age Threshold	Safety and efficacy in new-born patients (under 1 month) have not been established.
Reproductive Status	Use during pregnancy and lactation is only recommended where it is considered essential.

---

Approved Age Groups

Ranitidine is generally approved for use in adults and adolescents (12 years and over). Use is also established in children aged 3 to 11 years and infants aged 1 month to less than 3 years for approved indications under medical guidance.

The official interaction profile for Ranitidine Hydrochloride is defined by its pharmacokinetic effects on co-administered medicines and formal restrictions on combination therapy.

Interactions Altering Drug Exposure

The reduction of gastric acid secretion by Ranitidine may alter the systemic absorption and consequently reduce the exposure and effectiveness of products that require a low gastric pH for proper uptake. This interaction is formally documented for pH-dependent medicines, including specific antifungals, antivirals, and kinase inhibitors such as Atazanavir, Dasatinib, and Ketoconazole.

Conversely, some substances may increase exposure: Propantheline slightly delays and increases Ranitidine's peak plasma levels. Official data shows that co-administration with Triazolam results in increased Triazolam exposure, with mean Area Under the Curve ( AUC) values rising by up to 28%.

Restrictions and Timing Rules

Interaction restrictions include a prohibition on combining Ranitidine with other H2-receptor antagonists to avoid therapeutic duplication. Simultaneous administration of high-potency antacids is officially documented to decrease Ranitidine's absorption, requiring administration separation.

Coagulation and Food

While formal pharmacokinetic studies showed no interaction with Warfarin, reports exist of altered prothrombin times (increased or decreased) during concurrent use. The product's absorption is not significantly impaired by food.

How Ранитидин Софарма Works

The action of Ranitidine is a process of targeted receptor blockade that acts directly on the signaling pathways regulating gastric acid secretion.

Selective Blockade of the Histamine H2 Receptor

Ranitidine acts as a competitive antagonist at the Histamine H2 receptor located on the gastric parietal cell membrane. By occupying this receptor, the drug prevents the natural chemical messenger, histamine, from initiating the molecular cascade that stimulates acid secretion.

Modulating the Basal Acid Secretion Pathway

The drug's antagonism suppresses the intracellular signaling cascade (involving cAMP) that normally activates the final Proton Pump ( H^+/ K^+-ATPase). The mechanism demonstrates greater influence on the basal and nocturnal production of acid, resulting in an altered physiological output: a reduction in the hydrogen ion concentration and overall volume of gastric secretions.

Mechanistic Constraints on Total Acid Output

The H2 blockade mechanism does not interfere with acid secretion signals driven by gastrin or acetylcholine, which are active especially after meals. This means the drug modulates the acid output rather than eliminating it entirely, which establishes the physiological constraint of the mechanism.

The administration of Ranitidine Hydrochloride follows strictly defined regulatory guidelines covering the approved routes, standardized dosage, frequency, and specific context of use.

Administration Routes and Forms

The medicine is available for both oral administration using film-coated tablets, and parenteral administration via a solution for injection. Parenteral administration, which includes intramuscular (IM) and intravenous (IV) injection (as a bolus, intermittent, or continuous infusion), is generally reserved for short-term use in clinical settings where the oral route is not feasible.

Standard Dosing and Frequency

For the treatment of active conditions, the standard oral regimen is 150 mg taken twice daily, or alternatively, 300 mg administered as a single dose once daily. Prophylactic maintenance therapy typically involves a lower, 150 mg oral dose once daily. The injectable dose is 50 mg administered every 6 to 8 hours. Official instructions specify that the total IV or IM dose should generally not exceed 400 mg within a 24-hour period.

Contextual Use and Adjustments

Specific guidance exists for administration timing: the once-daily oral dose is instructed to be taken either after the evening meal or at bedtime. For IV administration, the injection solution must be diluted to specific concentrations depending on the method (bolus or infusion) prior to use. A mandatory dosage reduction is required for patients with documented renal impairment (creatinine clearance less than 50 mL/min). In these cases, the oral dose is typically reduced to 150 mg once daily. The duration of treatment for active conditions is typically 4 to 8 weeks, though maintenance regimens may be extended up to one year.

Research evidence / Overview of studies for Ранитидин Софарма

---

Evidence for the Treatment and Prevention of Duodenal and Gastric Ulcers

The research examining the use of this medicine for stomach and intestinal ulcers was studied for across numerous short-term Randomized Controlled Trials. The main outcomes monitored included the objective endoscopic documentation of ulcer healing rates and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies related to the duration over which healing outcomes were measured. Research explored whether healing outcomes measured in these studies had a longer required treatment duration compared to those measured in studies of certain other drug classes. Further research explored long-term controlled follow-up settings, which monitored patients for patterns related to ulcer recurrence.

---

Evidence for Gastroesophageal Reflux Disease (GERD) and Heartburn

Studies focusing on conditions characterized by fluctuating manifestations like GERD have included short-term clinical trials and systematic reviews. Research examined outcomes related to physical discomfort, primarily focusing on the frequency and severity of heartburn. Other studies monitored the healing of physical lesions in the esophagus. Studies reported measurements of symptom change in some patients during the study period. Comparative research has explored whether certain other drug classes show different patterns in the speed and completeness of symptom change. High-quality randomized data focusing on infants and children is generally less numerous compared to the adult population.

---

Evidence for Conditions of Pathological Gastric Acid Hypersecretion

This medicine was studied for conditions involving the stomach secreting an excessive amount of acid, such as Zollinger-Ellison Syndrome. The research utilized historical clinical trials, case series, and dedicated acid secretory studies. Outcomes monitoring physiological strain included the objective measurement of Basal Acid Output (BAO) and the ability to maintain a sustained increase in intragastric pH to target levels. Studies consistently reported measurements describing the change in volume and acidity of gastric secretions in the observed populations. Due to the rarity of certain hypersecretory conditions, evidence often relies on smaller patient cohorts and observational data, leading to evidence that is limited and heterogeneous in scope.

---

Long-Term Research and Durability of Response

Research exploring long-term outcomes included studies monitoring patients for patterns related to ulcer recurrence, with follow-up durations sometimes lasting up to several years. These studies monitored the maintenance of healing outcomes and the frequency of recurrence in patients on maintenance regimens. Findings describe group patterns related to ulcer recurrence measurements in maintenance treatment cohorts compared to un-treated groups. It is important to note that the follow-up durations were limited in many studies, and comprehensive long-term outcomes are not fully established beyond the specific periods studied. Furthermore, comparative evidence is lacking for the long-term durability of this medicine against alternative modern treatments used today.

Common questions about Ранитидин Софарма (FAQ)

Q: How should I store Ранитидин Софарма?

The medication should typically be stored at room temperature, away from moisture and heat, and kept out of the reach of children. Always refer to the specific instructions provided on the product packaging or in the patient leaflet for precise storage guidelines.

Q: Can I stop taking Ранитидин Софарма once my symptoms improve?

Stopping any prescribed treatment should only be done after consulting with a healthcare professional. They can evaluate your condition and determine if it is appropriate to discontinue or change your regimen.

Q: Does Ранитидин Софарма cause drowsiness, and can I drive while taking it?

The official product information does not commonly list drowsiness as a frequent side effect for this medication. However, any individual can react differently to medication. It is advisable to understand how the drug affects you before driving or operating heavy machinery. If you experience dizziness or fatigue, avoid these activities and speak with your doctor.

How to Store and Dispose of Ranitidine Sopharma

Storage Requirements

Ranitidine Sopharma tablets must be stored at a temperature not exceeding 25°C (77°F). It is mandatory to keep the medicine in the original container to provide protection from both light and moisture, which helps maintain product stability.

Handling and Disposal

For safety, the medicine must be stored out of the sight and reach of children.

Expired or unused Ranitidine Sopharma must not be disposed of in household waste or wastewater. The official instruction is to return the unused product to a pharmacy or dispose of it according to local regulatory requirements. For home disposal where take-back is unavailable, the product may be mixed with an unappealing substance and sealed in a bag before discarding in the trash.